JPMorgan Cuts Centene PT; UnitedHealth Up 1.1% 03/31/26
/
RSS Feed
JPMorgan Cuts Centene PT; UnitedHealth Up 1.1% 03/31/26
Key Stories:
- JPMorgan has adjusted its outlook on Centene Corporation, the managed care organization, cutting its price target to $41 from $45, while maintaining a Neutral rating on the shares. This move comes as Centene has seen a significant 16% selloff in its stock over the past week, signaling investor caution. Analysts are keeping a close eye on the stock’s performance, reminding us that even companies with good earnings growth can face headwinds. Investors will be watching if Centene can regain momentum following this analyst downgrade. Read more
- Sticking with the healthcare sector for a moment, shares of UnitedHealth, the diversified healthcare and insurance giant, saw a modest gain of 1.1% on Monday, closing the session at $261.79. This positive movement for UnitedHealth offers a contrast to some of the recent pressures seen elsewhere in the managed care space. Meanwhile, over in the financial sector, investment banking powerhouse Morgan Stanley edged slightly lower during Monday’s trading, settling at $158.37. These movements highlight the current mixed signals across different market segments, urging investors to remain selective. Read more
- Looking at a broader trend within the healthcare landscape, the global kidney cancer drugs market is projected for robust expansion. Reports indicate this vital market is expected to grow from $8.53 billion in 2025 to $8.88 billion by 2026, representing a solid 4.1% compound annual growth rate. Even more impressively, it’s forecasted to reach $10.82 billion by 2030, accelerating to a 5.1% CAGR. This growth signals strong opportunities for pharmaceutical giants like Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer, who are leading this critical therapeutic area. It’s definitely a segment of the healthcare industry worth keeping on your radar. Read more
Keywords: Bayer, Bristol Myers Squibb, CAGR, CNC, Centene, Exelixis, JPMorgan, MS, Morgan Stanley, Novartis, Pfizer, Roche, UNH, UnitedHealth, analyst rating, financial sector, healthcare sector, healthcare stocks, kidney cancer, managed care, market growth, market trends, pharmaceuticals, price target, stock performance, stock selloff